Irsogladine maleate and rabeprazole in non-erosive reflux disease - a double-blind, placebo- controlled study

Irsogladine maleate and rabeprazole in non-erosive reflux disease - a double-blind, placebo- controlled study - Irsogladine maleate and rabeprazole in NERD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015731

Enrollment

100

Registered

2014-11-21

Start date

2008-08-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NERD

Interventions

rabeprazole plus irsogladine maleate rabeprazole plus placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with persistent GERD symptoms were enrolled to participate in the study if they did not have mucosal breaks in their esophagi, and if they had Frequency Scale for Symptoms of GERD (FSSG) scores of 8 or more than 8.

Exclusion criteria

Exclusion criteria: Patients were excluded from the study if they were younger than 20 years, were allergic to rabeprazole or IM, had any level of esophagitis determined by gastrointestinal endoscopy, were pregnant, were taking anti-coagulant or anti-platelet agents, had a history of gastrointestinal malignancy, peptic ulcers, or gastrointestinal tract surgery, or if they had used any PPI therapy within four weeks of enrolling in the study.

Design outcomes

Primary

Measure	Time frame
FSSG(frequency scale for the symptoms of GERD)	—

Secondary

Measure	Time frame
SF-36(MOS Short-Form 36-Item Health Survey)	—

Countries

Japan

Contacts

Public ContactTakayoshi Suzuki

Tokai University School of Medicine Division of Gastroenterology & Hepatology

takayosh@is.icc.u-tokai.ac.jp0463-93-1121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026